Fortrea Holdings (FRA:K67) Total Equity: €455 Mil (As of Mar. 2026)


FRA:K67 Fortrea Holdings Inc FRA:K67
64 GF Score
Price €15.30
GF Value €14.91
! 7 Warning Signs
View Full Analysis

What is Fortrea Holdings Total Equity?

Fortrea Holdings FRA:K67 +4.79% 64 Total Equity is €455 Mil as of Mar. 2026. GuruFocus rates FRA:K67 with a GF Score™ of 64/100 and a GF Value™ of €14.91. The stock has 7 warning signs investors should review.

Fortrea Holdings's total equity for the quarter that ended in Mar. 2026 was €455 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Fortrea Holdings Total Equity Historical Data

* Premium members only.

The historical data trend for Fortrea Holdings's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fortrea Holdings Total Equity Chart

Fortrea Holdings Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial 2,885.63 3,155.41 1,571.83 1,301.09 481.23

Fortrea Holdings Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 794.39 510.84 494.84 481.23 454.90
FRA:K67
64GF Score
Fortrea Holdings Inc FRA:K67
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fortrea Holdings Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Fortrea Holdings's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=2319.208-1837.979
=481

Fortrea Holdings's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=2321.141-1866.237
=455

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €455 Mil mean?
Fortrea Holdings (FRA:K67) has a Total Equity of €455 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Fortrea Holdings and its competitors.
Is Fortrea Holdings' Total Equity too high?
Fortrea Holdings' current Total Equity is €455 Mil. Overall, Fortrea Holdings has a GF Score™ of 64/100, reflecting its overall financial health beyond just this single metric.
How does Fortrea Holdings' Total Equity compare to SEPN and MLTX?
Fortrea Holdings' Total Equity of €455 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Fortrea Holdings and its competitors. Fortrea Holdings's current Total Equity is €455 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fortrea Holdings stock overvalued right now?
Fortrea Holdings (FRA:K67) has a current Total Equity of €455 Mil. The stock's GF Value™ is €14.91, compared to a current price of €15.30 — trading 2.6% above its estimated fair value. The current Total Equity is €455 Mil. Fortrea Holdings' overall GF Score™ is 64/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Fortrea Holdings (FRA:K67), the current Total Equity is €455 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fortrea Holdings (FRA:K67) Overvalued in 2026?

Based on GuruFocus' analysis, Fortrea Holdings stock appears to be overvalued. The current stock price of €15.30 is trading 2.6% above its estimated GF Value™ of €14.91.

Key valuation signals for FRA:K67:

  • Total Equity: €455 Mil
  • GF Value™: €14.91 vs. price of €15.30 (2.6% above fair value)
  • GF Score™: 64/100 with 7 warning signs

No single metric tells the full story. See the FRA:K67 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Fortrea Holdings Business Description

Other Exchanges FTRE:USAK67:Germany
Address 8 Moore Drive, Durham, NC, USA, 27713
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.
64GF Score

Get the complete analysis for FRA:K67

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€15.30
Price
€14.91
GF Value